NCT05584644View on ClinicalTrials.gov

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions
Breast CancerBreast CarcinomaBreast NeoplasmsBreast TumorsCancer of Breast
Interventions
DRUG

Palbociclib plus hormonal treatment - first line treatment

Palbociclib plus hormonal treatment

DRUG

Palbociclib plus hormonal treatment - second line treatment

Palbociclib plus hormonal treatment

Trial Locations (6)

110017

Max Super Speciality Hospital, Saket Institutional Area,

110092

Max Super Speciality Hospital, Patparganj

302018

Bhagwan Mahaveer Cancer Hospital and Research Centre, Bajājnagar

380054

Hemato Oncology Clinic Ahmedabad Private Limited, Rajpath Club Lane ,Gujarat, India

380060

HCG Cancer Centre, Ahmedabad

500034

Indo-American Hospital, Nandi Nagar, Banjara Hills

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05584644 - A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | Biotech Hunter | Biotech Hunter